MA50213A - Peptide de transduction cytoplasmique et messager intracellulaire le comprenant - Google Patents

Peptide de transduction cytoplasmique et messager intracellulaire le comprenant

Info

Publication number
MA50213A
MA50213A MA050213A MA50213A MA50213A MA 50213 A MA50213 A MA 50213A MA 050213 A MA050213 A MA 050213A MA 50213 A MA50213 A MA 50213A MA 50213 A MA50213 A MA 50213A
Authority
MA
Morocco
Prior art keywords
intracellular messenger
transduction peptide
cytoplasmic transduction
messenger containing
cytoplasmic
Prior art date
Application number
MA050213A
Other languages
English (en)
Inventor
Yi Yong Baek
Min Jung Kim
Original Assignee
Avixgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avixgen Inc filed Critical Avixgen Inc
Publication of MA50213A publication Critical patent/MA50213A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA050213A 2016-12-16 2017-12-15 Peptide de transduction cytoplasmique et messager intracellulaire le comprenant MA50213A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160172548 2016-12-16

Publications (1)

Publication Number Publication Date
MA50213A true MA50213A (fr) 2020-07-22

Family

ID=62788380

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050213A MA50213A (fr) 2016-12-16 2017-12-15 Peptide de transduction cytoplasmique et messager intracellulaire le comprenant

Country Status (8)

Country Link
US (2) US20190315809A1 (fr)
EP (1) EP3556766A4 (fr)
JP (2) JP7221865B2 (fr)
KR (2) KR101964863B1 (fr)
CN (1) CN110139870B (fr)
AU (2) AU2017375828B2 (fr)
CA (1) CA3045599A1 (fr)
MA (1) MA50213A (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210254037A1 (en) * 2018-06-14 2021-08-19 Avixgen Inc. Pharmaceutical composition comprising fusion protein of cell-penetrating peptide and rpe65 for treatment of leber's congenital amaurosis
WO2022139487A1 (fr) 2020-12-22 2022-06-30 (주)메디엔진 Noveau peptide et son utilisation
KR20220139079A (ko) * 2021-04-07 2022-10-14 (주)스템메디텍 세포 투과성 펩타이드 변이체 및 이의 용도
KR20230016804A (ko) 2021-07-27 2023-02-03 (주) 에빅스젠 세포막 투과 펩티드 및 이를 포함하는 세포내 전달체
KR20240027904A (ko) * 2022-08-22 2024-03-05 (주) 에빅스젠 용해도 개선용 펩티드 및 이를 포함하는 용해도 개선 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01224398A (ja) * 1988-03-03 1989-09-07 Kirin Brewery Co Ltd 新規ペプチド
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
EP0633942A1 (fr) * 1992-03-27 1995-01-18 Whitehead Institute For Biomedical Research Particules de hiv non infectieuses et utilisations
EP0693939A1 (fr) * 1993-04-14 1996-01-31 Roche Diagnostics GmbH Peptides de tranfert d'acides nucleiques et leur utilisation pour injecter des acides nucleiques dans des cellules eucaryotes
US7101676B2 (en) 2002-01-11 2006-09-05 Douglas Buechter Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA
WO2005030968A2 (fr) * 2003-09-25 2005-04-07 Monsanto Technology Llc Elements regulateurs de l'actine, destines a des plantes
US20070099276A1 (en) 2003-10-25 2007-05-03 David Ott Retrovirus-like particles and retroviral vaccines
AU2003304566A1 (en) * 2003-10-25 2005-06-17 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Retrovirus-like particles and retroviral vaccines
US20080039528A1 (en) * 2004-03-17 2008-02-14 Kansas State University Research Foundation Zinc finger ejectors and methods of use thereof
JP4596391B2 (ja) * 2005-02-10 2010-12-08 国立大学法人大阪大学 細胞透過性ペプチド
EP1991560B1 (fr) * 2006-02-20 2018-04-04 Ewha University-Industry Collaboration Foundation Peptide présentant une activité de pénétration de membrane cellulaire
GB2458419B (en) * 2006-12-20 2011-02-16 Ji-Chang You Vector for expressing NC protein of HIV and method for producing NC protein using the same
CN101343327B (zh) * 2008-08-13 2012-05-23 汕头大学医学院 一种抗病毒蛋白质及其应用
PL2433953T3 (pl) * 2009-05-20 2015-12-31 Toray Industries Peptydy o zdolności przenikania przez błonę komórkową
WO2012118092A1 (fr) * 2011-03-01 2012-09-07 タカラバイオ株式会社 Protéine hybride
KR101135460B1 (ko) 2011-09-21 2012-06-27 대한민국 세포막 투과용 단백질 및 그 용도
JP2015512246A (ja) * 2012-03-15 2015-04-27 パーミオン バイオロジクス， インコーポレイテッド 細胞内抗体および抗体様モイエティの送達のための細胞透過組成物ならびに使用方法
KR101448800B1 (ko) * 2012-10-24 2014-10-13 한양대학교 산학협력단 핵산 전달 복합체
CN103897032A (zh) * 2012-12-28 2014-07-02 浙江日升昌药业有限公司 一种新型细胞穿膜肽

Also Published As

Publication number Publication date
JP7221865B2 (ja) 2023-02-14
AU2021202033A1 (en) 2021-04-29
KR20180070496A (ko) 2018-06-26
US20210388029A1 (en) 2021-12-16
KR20180118581A (ko) 2018-10-31
KR101964863B1 (ko) 2019-04-02
EP3556766A4 (fr) 2020-07-22
CA3045599A1 (fr) 2018-06-21
US20190315809A1 (en) 2019-10-17
JP2021098730A (ja) 2021-07-01
CN110139870A (zh) 2019-08-16
JP2020504090A (ja) 2020-02-06
CN110139870B (zh) 2023-12-01
AU2017375828B2 (en) 2021-04-15
AU2017375828A1 (en) 2019-05-30
EP3556766A1 (fr) 2019-10-23

Similar Documents

Publication Publication Date Title
MA50213A (fr) Peptide de transduction cytoplasmique et messager intracellulaire le comprenant
IL273432A (en) Protein compounds and their uses
IL279505A (en) Chimeric transmembrane protein and its uses
CL2017001864S1 (es) Soporte o stand de máquina de afeitar
IL271696A (en) Agonist antibodies that bind human CD137 and their use
EP3680567A4 (fr) Dispositif d'estimation de concentration
EP3521427A4 (fr) Co-récepteur de récepteur odorant
SG11202002880UA (en) Plant-protein based texturized oil-in-water emulsions
GB201820557D0 (en) Inertial exciter
SG11202001206YA (en) Emulsions, methods and uses thereof
HK1255381A1 (zh) 油包水型乳化化妝品
ZA201906954B (en) Btla agonist antibodies and uses thereof
MA50834A (fr) Peptides de pénétration cellulaire pour administration antisens
EP3684789A4 (fr) Protéine enrichie et appauvrie en zéine
IL273898B (en) A vesicle-adsorbing transmembrane protein
GB201807633D0 (en) Oil-in-water emulsions
SG11201907290VA (en) Oil-in-water emulsion cosmetic composition
IL271906A (en) Dual-functional anchor system
EP3618371A4 (fr) Procédé et dispositif d'analyse de chemin de routage
SG11202105169WA (en) Transmembrane domain derived from human lrrc24 protein
IL269213A (en) Antigen receptors and their uses
EP3677245A4 (fr) Produit cosmétique en émulsion de type eau dans huile
GB201719871D0 (en) System and speech evaluation
GB201617924D0 (en) Proteins and users
GB201721720D0 (en) Phystosterol based spreadable emulsions